Global Rheumatic Fever Market, By Drug Class (Antibiotics, Disease-Modifying Anti-Rheumatic Drugs (Dmards), Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Anticonvulsant, Others), Route of Administration (Oral, Parenteral, Topical, Others), Diagnosis (Echocardiogram, Blood Tests, Electrocardiogram (ECG)), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the rheumatic fever market is anticipated to grow rapidly during the forecast period. In persons over the age of 50, rheumatic fever is the main cause of death. People aged 50 and up have a higher frequency of rheumatic disease and a higher mortality rate than younger people. One of the most common causes of disability is rheumatic fever. When strep throat or scarlet fever is left untreated, rheumatic fever can develop. Children are the ones who are most affected. It is uncommon in the United States because drugs successfully treat bacterial infections.
Data Bridge Market Research analyses that the rheumatic fever market was valued at USD 1.254 billion in 2021 and is expected to reach USD 1.78 billion by 2029, registering a CAGR of 4.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Rheumatic fever is an infectious inflammatory illness that can develop as a result of an untreated case of strep throat. In certain people, rheumatic fever can cause long-term damage to the heart and heart valves. It arises as a result of a long-lasting case of group A streptococcal pharyngitis. It can damage the connective tissues of the skin, as well as the joints, heart, and blood vessels. Fever, muscular aches, swollen and aching joints, and, in some cases, a red, lattice-like rash usually appear two to four weeks after a strep infection. Rheumatic fever can also produce Sydenham's chorea, a transient nervous system condition that was originally known as St. Vitus' dance. This is a neurological condition marked by quick, jerky, involuntary movements of the body, which usually affect one side of the body more than the other.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Antibiotics, Disease-Modifying Anti-Rheumatic Drugs (Dmards), Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Anticonvulsant, Others), Route of Administration (Oral, Parenteral, Topical, Others), Diagnosis (Echocardiogram, Blood Tests, Electrocardiogram (ECG)), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Merck & Co., Inc. (US), Allergan (Ireland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Cipla Inc. (US), Abbott (US), AbbVie Inc. (US), Merck KGaA (Germany), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Dr. Reddy’s Laboratories Ltd. (India), Glenmark Pharmaceuticals Limited (India), Amneal Pharmaceuticals LLC. (US)
|
|
Market Opportunities
|
|
Rheumatic Fever Market Dynamics
Drivers
- Increasing incidences of strep throat
The rising incidences of strep throat is anticipated to propel the rheumatic fever market's growth rate. Rheumatic fever is an autoimmune inflammatory disease that can develop as a result of strep throat that hasn't been properly treated. Strep throat is a bacterial infection caused by the Streptococcus bacteria of group A.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of rheumatic fever market is the rising healthcare expenditure which helps in improving its infrastructure.
- Growing geriatric population
According to the United Nations Department of Economic and Social Affairs, there were around 901 million people aged 60 and up in the world in 2015, and this number is likely to rise significantly during the forecast period of 2022 to 2029. When compared to younger people, people over 50 and up have a higher incidence of rheumatic disease and a higher mortality rate. Hence, rising number of geriatric population is anticipated to flourish the market’s growth rate.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the rheumatic fever market. Additionally, high disposable income and continuously changing lifestyle pf people will result in the expansion of rheumatic fever market. Along with this, rising number of people with weak immune system will increase the risk of rheumatic fever and estimated to enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the rheumatic fever market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the rheumatic fever market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment of rheumatic fever will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the rheumatic fever market. Additionally, a decline in clinical visits due to COVID-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This rheumatic fever market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rheumatic fever market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
In comparison to developed countries, the incidence rate of rheumatic fever is higher in developing countries. According to the Centers for Disease Control and Prevention (CDC), arthritis affects roughly 23% of adults in the United States, or over 54 million individuals. The disease is estimated to impact 78 million adults in the United States by 2040. Rheumatic fever is one of the most common causes of disability. The disease's direct medical costs are more than USD 81 million each year. Women are more likely than men to have this condition.
Rheumatic fever market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Rheumatic Fever Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of multiple sclerosis in recent months.
Global Rheumatic Fever Market Scope
The rheumatic fever market is segmented on the basis of drug class, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Antibiotics
- Disease-Modifying Anti-Rheumatic Drugs (Dmards)
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
- Anticonvulsant
- Others
Diagnosis
- Echocardiogram
- Blood Tests
- Electrocardiogram (ECG)
Route of Administration
- Oral
- Parenteral
- Topical
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Rheumatic Fever Market Regional Analysis/Insights
The Rheumatic fever market is analysed and market size insights and trends are provided by country, drug class, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Rheumatic fever market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the rheumatic fever market because of the growing prevalence of rheumatic fever in this region. Additionally, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to large number of generic manufacturers and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Rheumatic Fever Market Share Analysis
The Rheumatic fever market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rheumatic fever market.
Some of the major players operating in the rheumatic fever market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Abbott (US)
- Merck KGaA (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Glenmark Pharmaceuticals Limited (India)
- Amneal Pharmaceuticals LLC. (US)
- Bayer AG (Germany)
SKU-